Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Oligometastatic non–small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to achieve a better clinical outcome. However, current definitions of oligometastasis are solely numerical, which are imprecise because of ignoring the biological heterogeneity caused by genomic characteristics. Our study aimed to profile the molecular alterations of oligometastatic NSCLC and elucidate its potential difference from polymetastasis. Materials and Methods We performed next-generation sequencing to analyze tumors and paired peripheral blood from 77 oligometastatic and 21 polymetastatic NSCLC patients to reveal their genomic characteristics and assess the genetic heterogeneity. Results We found ERBB2, ALK, MLL4, PIK3CB, and TOP2A were mutated at a significantly lower frequency in oligometastasis compared with polymetastasis. EGFR and KEAP1 alterations were mutually exclusive in oligometastatic group. More importantly, oligometastasis has a unique significant enrichment of apoptosis signaling pathway. In contrast to polymetastasis, a highly enriched COSMIC signature 4 and a special mutational process, COSMIC signature 14, were observed in the oligometastatic cohort. According to OncoKB database, 74.03% of oligometastatic NSCLC patients harbored at least one actionable alteration. The median tumor mutation burden of oligometastasis was 5.00 mutations/Mb, which was significantly associated with smoking, DNA damage repair genes, TP53 mutation, SMARCA4 mutation, LRP1B mutation, ABL1 mutation. Conclusion Our results shall help redefine oligometastasis beyond simple lesion enumeration that will ultimately improve the selection of patients with real oligometastatic state and optimize personalized cancer therapy for oligometastatic NSCLC.
Abstract
Purpose Oligometastatic non–small cell lung cancer (NSCLC) patients have been increasingly regarded as a distinct group that could benefit from local treatment to achieve a better clinical outcome. However, current definitions of oligometastasis are solely numerical, which are imprecise because of ignoring the biological heterogeneity caused by genomic characteristics. Our study aimed to profile the molecular alterations of oligometastatic NSCLC and elucidate its potential difference from polymetastasis. Materials and Methods We performed next-generation sequencing to analyze tumors and paired peripheral blood from 77 oligometastatic and 21 polymetastatic NSCLC patients to reveal their genomic characteristics and assess the genetic heterogeneity. Results We found ERBB2, ALK, MLL4, PIK3CB, and TOP2A were mutated at a significantly lower frequency in oligometastasis compared with polymetastasis. EGFR and KEAP1 alterations were mutually exclusive in oligometastatic group. More importantly, oligometastasis has a unique significant enrichment of apoptosis signaling pathway. In contrast to polymetastasis, a highly enriched COSMIC signature 4 and a special mutational process, COSMIC signature 14, were observed in the oligometastatic cohort. According to OncoKB database, 74.03% of oligometastatic NSCLC patients harbored at least one actionable alteration. The median tumor mutation burden of oligometastasis was 5.00 mutations/Mb, which was significantly associated with smoking, DNA damage repair genes, TP53 mutation, SMARCA4 mutation, LRP1B mutation, ABL1 mutation. Conclusion Our results shall help redefine oligometastasis beyond simple lesion enumeration that will ultimately improve the selection of patients with real oligometastatic state and optimize personalized cancer therapy for oligometastatic NSCLC.
참고문헌 (58)
- Roach MC, "Stereotactic body radiation therapy for central early-stage NSCLC : results of a prospective phase I", II Trial, 2018, pp.13, 1727~1732
- Postmus PE, "Early and locally advanced non-small-cell lung cancer(NSCLC) : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 28, pp.iv1~21 (2017)
- Rusthoven KE, "Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis", Acta Oncol, 48, pp.578~583 (2009)
- Hellman S, "Oligometastases", J Clin Oncol, 13, pp.8~10 (1995)
- Chang JY, "Optimize local therapy for oligometastatic and oligoprogressive non-small cell lung cancer to enhance survival", J Natl Compr Canc Netw, 20, pp.531~539 (2022)
- Iyengar P, "Consolidative radiotherapy for limited metastatic non-small-cell lung cancer : a phase 2 randomized clinical trial", JAMA Oncol, 4, pp.e173501~ (2018)
- Gomez DR, "Local Consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer : long-term results of a multi-institutional, phase II, randomized study", J Clin Oncol, 37, pp.1558~1565 (2019)
- Bauml JM, "Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer : a phase 2 trial", JAMA Oncol, 5, pp.1283~1290 (2019)
- 임채홍, "Role of Local Treatment for Oligometastasis: A Comparability Based Meta-Analysis", Cancer Research and Treatment, 54(4), pp.953~969 (2022), 대한암학회[DOI]
- Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- Cibulskis K, "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat Biotechnol, 31, pp.213~219 (2013)
- McKenna A, "The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Robinson JT, "Integrative genomics viewer", Nat Biotechnol, 29, pp.24~26 (2011)
- Wang K, "ANNOVAR : functional annotation of genetic variants from high-throughput sequencing data", Nucleic Acids Res, 38, pp.e164~ (2010)
- Forbes SA, "COSMIC : somatic cancer genetics at high-resolution", Nucleic Acids Res, 45, pp.D777~83 (2017)
- Blokzijl F, "MutationalPatterns : comprehensive genome-wide analysis of mutational processes", Genome Med, 10, pp.33~ (2018)
- Chakravarty D, "OncoKB: a precision oncology knowledge base", JCO Precis Oncol, 2017 (2017)
- Schumacher TN, "Neoantigens in cancer immunotherapy", Science, 348, pp.69~74 (2015)
- Subbiah V, "The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden(TMB)≥10 : a decision centered on empowering patients and their physicians", Ann Oncol, 31, pp.1115~1118 (2020)
- Teo MY, "Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1", PD-L1 blockade in advanced urothelial cancers, 2018, pp.36, 1685~1694
- Landrum MJ, "ClinVar : public archive of interpretations of clinically relevant variants", Nucleic Acids Res, 44, pp.D862~8 (2016)
- Adzhubei IA, "A method and server for predicting damaging missense mutations", Nat Methods, 7, pp.248~249 (2010)
- Yu G, "clusterProfiler : an R package for comparing biological themes among gene clusters", OMICS, 16, pp.284~287 (2012)
- Alexandrov LB, "Mutational signatures associated with tobacco smoking in human cancer", Science, 354, pp.618~622 (2016)
- Helleday T, "Mechanisms underlying mutational signatures in human cancers", Nat Rev Genet, 15, pp.585~598 (2014)
- Kim JH, "Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma", Cancer Med, 10, pp.3197~3204 (2021)
- Huang RS, "Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases", Oncologist, 27, pp.839~848 (2022)
- Hellmann MD, "Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden", N Engl J Med, 378, pp.2093~2104 (2018)
- Chan TA, "Development of tumor mutation burden as an immunotherapy biomarker : utility for the oncology cli-nic", Ann Oncol, 30, pp.44~56 (2019)
- Wang Z, "Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel", JAMA Oncol, 5, pp.696~702 (2019)
- Chalmers ZR, "Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
- Cremolini C, "Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer(TRIBE2) : a multicentre, open-label, phase 3, randomised, controlled trial", Lancet Oncol, 21, pp.497~507 (2020)
- Chen Z, "Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers", Front Cell Dev Biol, 9, pp.808208~ (2021)
- Offin M, "Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers", Clin Cancer Res, 25, pp.1063~1069 (2019)
- Chen H, "Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades", Front Immunol, 10, pp.1113~ (2019)
- Schoenfeld AJ, "The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer", Clin Cancer Res, 26, pp.5701~5708 (2020)
- Ettinger DS, "NCCN guidelines insights : non-small cell lung cancer, version 2. 2021", J Natl Compr Canc Netw, 19, pp.254~266 (2021)
- Planchard D, "Metastatic non-small cell lung cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 29, pp.iv192~237 (2018)
- Robinson D, "Integrative clinical genomics of advanced prostate cancer", Cell, 161, pp.1215~1228 (2015)
- Egolf S, "MLL4 mediates differentiation and tumor suppression through ferroptosis", Sci Adv, 7, pp.eabj9141~ (2021)
- Whale AD, "Functional characterization of a novel somatic oncogenic mutation of PIK3CB", Signal Transduct Target Ther, 2, pp.17063~ (2017)
- Cancer Genome Atlas Research Network, "Comprehensive genomic characterization of squamous cell lung cancers", Nature, 489, pp.519~525 (2012)
- Cancer Genome Atlas Research Network, "Comprehensive molecular profiling of lung adenocarcinoma", Nature, 511, pp.543~550 (2014)
- Frank R, "Clinical and pathological characteristics of KEAP1-and NFE2L2-mutated non-small cell lung carcinoma(NSCLC)", Clin Cancer Res, 24, pp.3087~3096 (2018)
- Blackford AN, "ATM, ATR, and DNA-PK : the trinity at the heart of the DNA damage response", Mol Cell, 66, pp.801~817 (2017)
- Mayer IA, "A phase Ib study of alpelisib(BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ER+", HER2-metastatic breast cancer, 2017, pp.23, 26~34
- Patnaik A, "First-in-human phase I study of copanlisib(BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas", Ann Oncol, 27, pp.1928~1940 (2016)
- Powles T, "Randomized open-label phase II trial of apitolisib(GDC-0980), a novel inhibitor of the PI3K", mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma, 2016, pp.34, 1660~1668
- Ma Z, "Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy", Antioxid Redox Signal, 34, pp.1484~1497 (2021)
- Negrini S, "Genomic instability : an evolving hallmark of cancer", Nat Rev Mol Cell Biol, 11, pp.220~228 (2010)
- Zhao S, "Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer", BMC Med, 19, pp.223~ (2021)
- Hong DS, "KRAS(G12C)inhibition with sotorasib in advanced solid tumors", N Engl J Med, 383, pp.1207~1217 (2020)
- Skoulidis F, "Sotorasib for lung cancers with KRAS p. G12C mutation", N Engl J Med, 384, pp.2371~2381 (2021)
- Alborelli I, "Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer", J Pathol, 250, pp.19~29 (2020)
- Ricciuti B, "Impact of DNA damage response and repair(DDR)gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer", Clin Cancer Res, 26, pp.4135~4142 (2020)
- Dong ZY, "Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma", Clin Cancer Res, 23, pp.3012~3024 (2017)
- Wang C, "Molecular subtyping and prognostic assessment based on tumor mutation burden in patients with lung adenocarcinomas", Int J Mol Sci, 20, pp.4251~ (2019)
- Wang S, "The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex", Int J Cancer, 145, pp.2840~2849 (2019)